Key facts
- Bonito Biosciences’s last known valuation is $42.0M (Oct 2025).
- It has raised $29.5M; the latest was Early Stage VC ($17.0M) in Oct 2025.
- Notable investors include JAZZ Venture Partners, Lightstone Ventures, Anterra Capital, Lightstone.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Bonito Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Bonito Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Bonito Biosciences
Developer of a targeted delivery platform designed to enable precise delivery of therapeutic payloads to defined cell and tissue types. The company offers small molecule and antibody discovery engines that create ligand-based delivery constructs, enabling biopharmaceutical developers to pursue RNA interference therapeutics, oncology applications, and small molecule drug discovery with high tissue specificity.
- Sector
- Healthcare
- HQ
- Waltham, MA, United States
- Founded
- 2022
- Employees
- 26
- Website
- bonitobio.com/
- Ownership
- Privately Held (backing)
Bonito Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Bonito Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Bonito Biosciences in its N-PORT filings yet. We sweep new filings monthly.